TPG – Buy

Posted on | by Leon Hinde

Buy TPG Telecom above the $5.06 higher low formation.

Traders should consider applying a stop loss below the recent pivot low of $4.81 or on a break of $5.06.

TPG offers solid free cash flow with an improving dividend story into FY22 and FY23.

Origin – Breakout

Posted on | by Leon Hinde

Origin Energy has broken out of a prolonged downtrend as the negative earnings cycle appears to be nearing the bottom.

The market has low expectations for FY22 earnings with EBITDA down almost 40% on FY21 and DPS falling from $0.14 to $0.10 placing the stock on an expected yield of 2.2%.

We see upside for Origin and suggest a stop loss below the recent $3.87 low.

Woodside – Rallies 10%

Posted on | by Leon Hinde

WPL:ASX is under Algo Engine buy conditions and is a current holding in our ASX model portfolio.

Buy WPL above the $21.50 support level.

4/6 Update: WPL has now rallied 10% from the pivot low and we see further upside potential supported by strong energy prices.

Bega – Update

Posted on | by Leon Hinde

Bega Cheese is under Algo Engine buy conditions and is a current holding in our ASX model portfolio.

Accumulate within the $5.50 – $5.70 price range.

4/6 Update: Bega has now rallied from Wednesday’s $5.64 low to be trading today at $5.90. Traders – stay long BGA whilst the price action remains above the 10 day average.

Investors – You may choose to simply hold the stock for yield and the likely compound 5 – 9% EPS growth.

IPL – 1H21 Result

Posted on | by Leon Hinde

Incitec Pivot is now under Algo Engine buy conditions.

The company reported 1H21 Sales of $1.72m with underlying EBITDA of $286m. The EBIT miss was primarily driven by Fertilizers and Dyno Americas, with Dyno APAC largely in-line.

Our Option Lab AI technology suggests looking at the following call.

3/6 Buy IPL

Call options are now trading $0.20 to $0.24

Cure ETF – Buy

Posted on | by Leon Hinde

CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.

ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.

.

Qube Holdings – Buy

Posted on | by Leon Hinde

Qube Holdings is under Algo Engine buy conditions.

Port volumes for April & May were stronger than analysts expected which adds support to the $3.50 price target for Qube.

Total container movements across Australia’s major ports have increased +11% compared to the same time last year.